Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026

Tuesday, May 3, 2016 Drug News J E 4

LONDON, May 3, 2016 /PRNewswire/ --

- And Other Rising Companies - a Market Report Assessing Developers and Producers of Those Competitor Biologics 

- Biosimilar Drug Producers - Your 2016 Guide to Companies' Activities and Prospects  

Who are the most important and promising biosimilar drug companies? And what are their sales potentials? Discover, in our updated survey, organisations' outlooks from 2016. There you see results, trends, opportunities and revenue forecasting.

Visiongain's new study analyses 25 leading developers, producers and marketers of biosimilars. That work also covers other firms, including big pharma companies entering that industry. There you assess potentials of established competitors and emerging players.

Our analysis is for everyone interested in the future of biopharma. Biosimilar drug sales expand fast, and that market holds great potential, especially after opening of the US market. See now how you could benefit your plans, decisions and authority.

Forecasts and other data to help you stay ahead in knowledge on those biological drugs In our updated report you find analytical profiles of 25 leading biosimilar drug companies. There you analyse products, sales results, R&D and prospects. See qualitative analyses, too, for those biologics, also with discussions of many other relevant firms.

Our study gives you 115 tables, 11 charts and three interviews with companies. That survey lets you assess the most lucrative parts of the industry for biosimilar drugs (follow-on biologics or subsequent entry biologics). Explore the future of those therapeutic proteins for human medicine and assess their producers.

So explore changes affecting the biological drugs industry from 2016. The following sections outline what you get in our new investigation, showing how it can help your work.

To see a report overview please email Sara Peerun on

Molecules giving rise to biosimilars - explore where progress occurs First our report discusses biosimilar competition for these five therapeutic agents - products and research and development: • Adalimumab • Infliximab • Etanercept • Darbepoetin alpha • Rituximab.

Large opportunities remain for biosimilars, with our study predicting high, rapid market expansion from 2016 to 2026. See what is possible. And discover where the best prospects exist and which companies are most likely to prosper.

That way you gain data and other knowledge to benefit your reputation for commercial insight. Assess products, technologies, activities and top biosimilar companies' potentials.

Leading biosimilar drug companies - see what they are doing, including their prospects In particular our survey analyses 25 leading biosimilar specialists worldwide. First of all, Chapter 4 gives profiles of leading biosimilar companies based in the US, Western Europe and Israel: • Sandoz • Teva Pharmaceutical Industries • Hospira • STADA Arzneimittel • Mylan.

Chapter 5 profiles leading companies in China: • 3SBio • Qilu Pharmaceutical • Shanghai Fosun Pharmaceutical Group • Tonghua Dongbao Pharmaceutical Co. • Beijing ShuangLu Pharmaceutical Co.

Chapter 6 profiles leading companies in India: • Biocon • Dr. Reddy's Laboratories • Wockhardt • Zydus Cadila • Ranbaxy • Reliance Life Sciences • Intas Biopharmaceuticals.

Chapter 7 profiles leading companies in Latin America: • Probiomed • Biosidus • Amega Biotech.

Chapter 8 profiles leading companies in the rest of the world: • Celltrion • LG Life Sciences • Dong-A • Bioton • Biocad.

Our report also reviews 25 other companies rising in importance. See what is possible from 2016, discovering what leading companies do and their commercial outlooks.

With our survey you explore who and what shapes the biosimilars industry, including policies and other forces influencing those companies and their market, affecting its revenues and profits. Discover what the future holds for leading organisations.

Issues affecting developers, producers and sellers of those biopharmaceuticals Our investigation explains influences and events affecting the biosimilars industry and market from 2016, including these forces: • Companies' technologies, strategies, collaborations, products, R&D and results • Emerging national markets and expanding therapeutic needs worldwide • Big pharma entering that market - a trend shaping that industry.

And you assess these effects, among others: • Patent expiries and resulting opportunities for follow-on products • Innovative biologics, including biobetters, and their influence on biosimilar sales • R&D for that market - assess technologies, clinical trials and opportunities, seeing how leading biosimilars companies adapt and progress.

There you examine political, economic, social and technological questions, assessing commercial outlooks. And you assess strengths, weaknesses, opportunities and threats affecting biosimilar drug companies' activities and results.

Developing and developed national markets will prove important for biosimilar drug sales from 2016 to 2026. Discover what the future holds and the expected gains, including overall world revenue forecasting to 2026 for the biosimilars industry.

5 Ways Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026 helps you Our new study helps your research, plans and analyses in these five main ways: • Profiles of 25 leading biosimilar companies and other relevant firms - assess products, results, strategies, technologies and outlooks, also gaining company level revenue forecasting for five leading producers' biosimilar drug sales • R&D for biosimilars - see activities by company, finding what goes on in that industry, investigating its technological and commercial potentials • Competition and opportunities - explore what affects the biosimilars market, finding what shapes its future, especially prospects for developing business • Interviews with 3 companies - discover views to help you stay ahead in knowledge on that expanding drugs market • Revenue forecasting to 2026 for that industry at world level - investigate overall sales potential there, seeing what revenue gains are possible.

Analysis found nowhere else, letting you explore the future of those biologics Our work - by visiongain's UK-based analysts - gives you independent research and analysis. There you get a review of that industry and data found only in our report. You explore the most promising market segments and assess leading companies' prospects.

With that investigation you are less likely to fall behind in knowledge. See how you could benefit your research, analysis and decisions. Also discover how you could save time and gain in recognition for insight on the biological drugs market, helping your influence.

Predictions for developing, producing and selling biosimilars - see now what is possible Our updated study shows you data, trends, opportunities and outlooks for producers and sellers of biosimilars and related medicines. That analysis is for everybody interested in the future of biopharmaceuticals. So avoid missing out - instead please get our report here now.

To see a report overview please email Sara Peerun on

To request an exec summary of this report please email Sara Peerun at or call Tel: +44 (0) 20 7336 6100

Or click on

Companies Listed  

3SBio Abbott Laboratories AbbVie Aché Actavis Adimab Alvogen Amega Biotech Amgen Apotex Aragen Bioscience ASKA Pharmaceuticals AstraZeneca Avesthagen Baxter International Beijing SL Pharmaceutical Bio Technology General Corporation Biocad Bioceuticals Biocon Biogen Idec. Biolab Sanus Farmacêutica BioMab Bionovis BioPartners Biosidus Biotech GmbH Biocon Bioton Biovel Life Sciences BioXpress Therapeutics Boehringer Ingelheim Brazil's National Economic Development Bank (BNDES) Brazilian Ministry of Health Brazilian Ministry of Science and Technology (MST) Bristol-Myers Squibb Catalent Pharma Solutions Celltrion China Israel Value Capital Chongqing Fochon Pharmaceutical Research Co. Cipla CITIC Group Clinigene Coherus Biosciences Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) Committee for Medicinal Products for Human Use (CHMP) Competitions Commission of India (CCI) Cristalía Daiichi Sankyo Dainippon Sumitomo Pharma Dong-A Pharmaceuticals Dr. Reddy's Laboratories Drugs Controller General of India Egis Pharmaceuticals Eisai Eli Lilly Emcure Pharmaceuticals EMS Epirus Pharmaceuticals Eurofarma European Medicines Agency (EMA) Financier of Studies and Projects (FINEP) Finox Biotech Food and Drug Administration (FDA) Forwell Biopharm Fosun Pharma Fuji Pharma Fujifilm Kyowa Kirin Biologics Gan & Lee Pharmaceutical Gedeon-Richter Generex Biotechnology Corporation GeneScience Gennova Genzyme German Remedies Germonta Holdings GlaxoSmithKline Hanwha Chemical Haselmeier Hetero Drugs Hospira Hualida Biotech Human Genome Sciences Hypermarcas Impax Laboratories Indian Clinical Trials Registry (CTRI) Innovent Biologics Intas Biopharmaceuticals Intas Pharmaceuticals Itero Biopharmaceuticals Janssen Biotech Japan's Ministry of Health, Labour and Welfare JCR Pharmaceuticals Johnson & Johnson Korean Food and Drug Administration (KFDA) Kwizda Pharmaceutical Kyowa Hakko Kirin Lallemand-Institut Rosell LG Life Sciences Libbs Farmacêutica Lonza Lupin MabPharm Marvel Life Sciences Medice Arzneimittel Pütter GmbH & Co. KG MedImmune Meiji Seika Pharmaceuticals Merck & Co. Merck KGaA Merck Serono Mindar Holdings Mitsubishi Tanabe MJ Biopharm MJ Bioton Life Sciences Mochida Pharmaceutical Momenta Pharmaceuticals Mylan National Autonomous University of Mexico (UNAM) National Council for Science and Technology (CONACyT) Nippon Kayaku NovaQuest Novartis Novo Nordisk Orygen Biotecnologia Oswaldo Cruz Foundation Parexel Pfenex Pfizer Pharmstandard Pliva Probiomed Qilu Pharmaceutical Ranbaxy Ratiopharm Recepta Retacrit Reliance Life Sciences Richter-Helm BioTec GmbH & Co. KG Rimsa Roche Samsung Bioepis Samsung BioLogics Sandoz Sanofi Savient Pharmaceuticals SciGen Selecta Biosciences Shanghai Celgen Biopharmaceutical Shanghai CP Guojian Shanghai Fosun Pharmaceuticals Shanghai Henlius Biotech Co. Shanghai Lansheng Guojian Pharmaceutical Co. Ltd Shanghai Pharmaceutical Group Shantha Biotechnics Shreya Shreya Life Sciences Sicor Biotech Sidus Pharmaceutical Group Simcere Sinopharm STADA Arzneimittel State's Employees´ Social Security and Social Services Institute (ISSSTE) Sun Pharmaceuticals Syngene Synthon Takeda Tat BioTech Holdings Limited Teva Pharmaceutical Industries Tonghua Dongbao União Química US Centers for Disease Prevention and Control (CDC) Wanbang Biopharmaceuticals Wockhardt World Health Organization (WHO) Wyeth Xiamen Amoytop Biotech Ypsomed Zenotech Laboratories Zhejiang Hisun Zuventus Zydus Biovation Zydus Cadila

To see a report overview please email Sara Peerun on

Media Contact: Sara Peerun

SOURCE Visiongain



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Caremerge Launches Redesign of Revolutionary Famil...
Stroke Victims Look to Innovative Glasses to Impro...